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Abstract
Background: Human T-cell leukemia virus type 1 (HTLV-1), the etiologic agent for adult T-cell
leukemia (ATL), induces cytokine-independent proliferation of T-cells, associated with the
acquisition of constitutive activation of Janus kinases (Jak) and signal transducers and activators of
transcription (Stat) proteins. Our purposes in this study were to determine whether activation of
Jak-Stat pathway is responsible for the proliferation and survival of ATL cells, and to explore
mechanisms by which inhibition of Jak-Stat pathway kills ATL cells.
Results: Constitutive activation of Stat3 and Stat5 was observed in HTLV-1-infected T-cell lines
and primary ATL cells, but not in HTLV-1-negative T-cell lines. Using AG490, a Jak-specific
inhibitor, we demonstrated that the activation of Stat3 and Stat5 was mediated by the constitutive
phosphorylation of Jak proteins. AG490 inhibited the growth of HTLV-1-infected T-cell lines and
primary ATL cells by inducing G1 cell-cycle arrest mediated by altering the expression of cyclin D2,
Cdk4, p53, p21, Pim-1 and c-Myc, and by apoptosis mediated by the reduced expression of c-IAP2,
XIAP, survivin and Bcl-2. Importantly, AG490 did not inhibit the growth of normal peripheral blood
mononuclear cells.
Conclusion:  Our results indicate that activation of Jak-Stat pathway is responsible for the
proliferation and survival of ATL cells. Inhibition of this pathway may provide a new approach for
the treatment of ATL.
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Background
Adult T-cell leukemia (ATL) is an aggressive lymphoprolif-
erative disorder that occurs in individuals infected with
human T-cell leukemia virus type 1 (HTLV-1) [1-3].
HTLV-1 causes ATL in 3–5% of infected individuals after a
long latent period of 40–60 years [4]. The prognosis of
ATL patients remains poor with a median survival time of
13 months in aggressive cases [5]. The poor prognosis of
ATL patients is partly due to the innate resistance of HTLV-
1-infected T-cells to apoptosis and thus to conventional
chemotherapy regimens. Therefore, there is a critical need
for new ATL therapies with improved efficacy over current
treatments.
High expression of the interleukin-2 receptor α chain (IL-
2Rα) is a common feature of ATL cells and HTLV-1-
infected T-cell lines [6]. One of the well-documented sig-
nalling pathways mediated by IL-2R is Janus kinase (Jak)-
Signal transducers and activators of transcription (Stat)
[7]. Jak proteins transduce signals by phosphorylating Stat
proteins, which in turn dimerize and translocate to the
nucleus to activate the expression of genes necessary for
cell proliferation and differentiation [8]. Abnormal activa-
tion of Stat proteins is a common characteristic found in
various human tumor cell lines and human tumors
including leukemia and lymphoma [9-11]. Constitutive
activation of the IL-2R-Jak/Stat signalling pathway corre-
lates with IL-2 independence of HTLV-1-transformed cell
lines [12]. Constitutive Jak1, Jak3, Stat1, Stat3 and Stat5
activation was observed in HTLV-1-infected T-cell lines
[13]. Similarly, an in vitro study with uncultured leukemic
cells from HTLV-1 seropositive patients with ATL also dis-
played constitutive activation of Jak3, Stat1, Stat3 and
Stat5 [14]. These results suggest that activation of the IL-
2R signalling pathway mediated by Jak-Stat may play a
key role in transformation by HTLV-1. However, a causal
relationship between carcinogenesis and activation of the
Jak-Stat pathway in ATL has not been established, and it is
not clear whether disruption of this pathway could reverse
the phenotypic condition of HTLV-1-infected T-cells.
AG490 is a recent addition to the synthetically derived tyr-
phostin family of tyrosine kinase inhibitors. Tyrphostins
were designed on the basis of tyrosine and erbstatin and
were all benzene malonitriles, many of which are sub-
strate competitive but non-competitive inhibitors with
respect to adenosine triphosphate [15]. AG490 selectively
inhibits Jak family kinases but has no effect on other lym-
phocyte tyrosine kinases, including Lck, Lyn, Btk, Syk and
Src [16,17]. Systemic administration of AG490 in SCID
mice with disseminated human leukemic cells dependent
on Jak2 for survival resulted in tumor cell apoptosis lead-
ing to complete tumor regression [16]. However, it has
been reported that AG490 blocks the phosphorylation of
Stat5 and Jak3, and DNA-binding activity of Stat5 of
HTLV-1-transformed T-cell lines, but it fails to disrupt the
growth of these leukemic cells [18]. In the present study,
we evaluated the anti-tumor efficacy of AG490 against
ATL and found that AG490 inhibited the growth of HTLV-
1-infected T-cell lines and primary ATL cells, but not that
of normal peripheral blood mononuclear cells (PBMCs).
Furthermore, we investigated the possible mechanisms
involved in such in vitro growth-inhibitory effect. Our
findings suggested that activation of Jak-Stat signalling
pathway is responsible for ATL cell proliferation and sur-
vival.
Results
Constitutive tyrosine phosphorylation of Stat3 and Stat5 
in HTLV-1-infected T-cell lines
We first examined HTLV-1-infected T-cell lines [MT-2,
HUT-102 and ED-40515(-)] for the phosphorylation sta-
tus of Stat3 and Stat5. All HTLV-1-infected T-cell lines dis-
played constitutive phosphorylation of Stat3 (Figure 1A,
top panel). Constitutive phosphorylation of Stat5 was
observed in MT-2 and HUT-102 (Figure 1A, third panel).
In contrast, phosphorylation of Stat3 and Stat5 was not
observed in HTLV-1-negative T-cell lines (Jurkat, MOLT-4
and CCRF-CEM) (Figure 1A, top and third panels),
although the expression of Stat3 and Stat5 was detected in
all cell lines (Figure 1A, second and forth panels). MT-2
and HUT-102 highly express HTLV-1 viral proteins,
whereas ED-40515(-), a T-cell line of leukemic cell origin
established from a patient with ATL, expresses little HTLV-
1 viral proteins. For example, HTLV-1 transforming pro-
tein Tax was detected in MT-2 and HUT-102, but not in
ED-40515(-) and all HTLV-1-negative T-cell lines (Figure
1A, second panel from the bottom). Because hypermeth-
ylation of 5' HTLV-1 long terminal repeat in ATL derived
cell lines and ATL cells silenced the viral gene expression
[19], ED-40515(-) cells did not express significant levels
of Tax protein. These results suggested that constitutive
phosphorylation of Stat3 and Stat5 seems to depend on
HTLV-1 infection, but not on the expression of HTLV-1
Tax protein.
Constitutive activation of Stat3- and Stat5-DNA binding 
activity in HTLV-1-infected T-cell lines
Electrophoretic mobility shift assay (EMSA) was per-
formed to analyze Stat-DNA binding activity of HTLV-1-
infected T-cell lines using two different Stat-consensus
sequences from the c-fos gene promoter [sis-inducible ele-
ment (SIE)] and from the β-casein  gene promoter (β-
casein) (Figure 1B). Both SIE- and β-casein-binding activ-
ities were detected in the nuclear extracts of MT-2 and
HUT-102 cells. SIE- but not β-casein-binding activity was
detected in extracts of ED-40515(-) cells. In contrast, no
significant DNA binding activity of SIE or β-casein was
detected in extracts of HTLV-1-negative T-cell lines. Com-
petition assays showed that the observed protein-DNARetrovirology 2006, 3:22 http://www.retrovirology.com/content/3/1/22
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complexes were specific for SIE or β-casein (Figures 1C).
The SIE-binding protein complexes from MT-2, HUT-102
and ED-40515(-) cells included Stat3, since the complex
was supershifted by specific antibody for Stat3 (Figure
1D). The β-casein-binding protein complexes from MT-2
and HUT-102 cells included Stat5 (Figure 1E, upper pan-
els). Stat1, Stat2 and Stat4 specific antibodies did not
influence the formation of both SIE- and β-casein-com-
plexes in any cell lines (Figures 1D and 1E). These results
indicate that constitutive phosphorylation of Stat3 and
Stat5 correlates with their DNA binding activities in
HTLV-1-infected T-cell lines.
Tax is not responsible for the induction of Stat3 and Stat5 
phosphorylation in T-cells
We next examined whether HTLV-1 Tax protein alters the
phosphorylation status of Stat3 and Stat5. Tax-inducible
T-cell line, JPX-9 expressed Tax 10 h after addition of
CdCl2 and the expression persisted until 72 h after treat-
ment (Figure 2, second panel from the bottom, lanes 4–
7). Although Stat3 and Stat5 were consistently expressed
in JPX-9 cells even after CdCl2 treatment, phosphorylated
Stat3 and Stat5 were not detected in these cells (Figure 2,
first and third panels). These results suggest that Tax is not
Constitutive activation of Stat3 and Stat5 in HTLV-1-infected  T-cell lines Figure 1
Constitutive activation of Stat3 and Stat5 in HTLV-1-
infected T-cell lines. (A) Western blot analysis of cellular 
lysates prepared from three HTLV-1-negative [HTLV-1 (-)] 
and three HTLV-1-infected [HTLV-1 (+)] T-cell lines. The 
blots were probed with anti-phospho-Stat3, anti-Stat3, anti-
phospho-Stat5, anti-Stat5 and anti-Tax. Amounts of actin are 
shown as loading controls. (B) Stat-DNA binding activities in 
HTLV-1-negative and HTLV-1-infected T-cell lines were 
detected by EMSA using SIE or β-casein probe. Arrows indi-
cate specific protein-DNA complexes. NS indicates non-spe-
cific bands. (C) Competition assay was performed with 
nuclear extracts of HTLV-1-infected cell lines using 100-fold 
excess of unlabeled wild type (W) or mutant (M) oligonucle-
otide as a competitor (upper panels: SIE, lower panels: β-
casein). (D and E) Involvement of Stat3 and Stat5 in the for-
mation of SIE- (D) and β-casein- (E) binding complexes in 
HTLV-1-infected T-cell lines. EMSA was performed with 
nuclear extracts of the indicated cell lines either in the 
absence (-) or presence of a specific Stat antibody (αStat: 
anti-Stat1, Stat2, Stat3, Stat4 and Stat5 antibodies). The 
supershifted complexes are indicated by arrowheads.
HTLV-1 Tax does not involve in phosphorylation of Stat3  and Stat5 Figure 2
HTLV-1 Tax does not involve in phosphorylation of 
Stat3 and Stat5. Cell lysates were prepared from CdCl2-
treated JPX-9 cells at the indicated time points (lanes 1–7) 
and untreated MT-2 cells (lane 8: as a positive control). The 
expression of phospho-Stat3, Stat3, phospho-Stat5, Stat5 and 
Tax (arrow) was analyzed by Western blot. Actin expression 
served as a loading control.Retrovirology 2006, 3:22 http://www.retrovirology.com/content/3/1/22
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involved in the induction of Stat3 and Stat5 phosphoryla-
tion in T-cells.
AG490 reduces constitutive activation of Stat3 and Stat5 
through inhibition of Jak kinases in HTLV-1-infected T-cell 
lines
The regulation of phosphorylation of Stat3 and Stat5 by
Jak kinases was investigated with Jak selective inhibitor,
AG490. AG490 reduced constitutive phosphorylation in
Stat3 [MT-2, HUT-102 and ED-40515(-)] and Stat5 (MT-
2 and HUT-102) in a dose-dependent manner (Figures 3A
and 3B). AG490 also suppressed constitutive phosphor-
ylation of Stat3 and Stat5 in freshly isolated ATL cells (Fig-
ure 3C). Constitutive phosphorylation of Jak1, Jak2 and
Jak3 was observed in MT-2 and HUT-102 cells, and treat-
ment of these cells with increasing concentrations of
AG490 resulted in significant inhibition of phosphoryla-
tion of Jak1, Jak2 and Jak3 (Figure 3D). Constitutive phos-
phorylation of Jak2 but not Jak1 and Jak3 was detected in
ED-40515(-) cells and treatment with AG490 inhibited
phosphorylation of Jak2 in ED-40515(-) cells (Figure
3D). AG490 did not affect on phosphorylation status of
glycogen synthase kinase-3β (GSK-3β) that is not regu-
lated by Jak-Stat pathway (Figure 3E), suggesting that
effect of AG490 is specific for Jak-Stat pathway. To deter-
mine whether AG490 inhibits DNA binding activity of
Stat3 and Stat5 in HTLV-1-infected T-cell lines, we treated
the cells with 50 µM AG490 for 24 h and performed EMSA
(Figure 3F). AG490 decreased SIE- [MT-2, HUT-102 and
ED-40515(-)] and β-casein- (MT-2 and HUT-102) DNA
binding activity of HTLV-1-infected T-cell lines. These
results suggest that AG490 reduces the constitutive activa-
tion of Stat3 and Stat5 by inhibiting three Jak kinases in
HTLV-1-infected T-cell lines.
AG490 inhibits the cell growth of HTLV-1-infected T-cell 
lines and primary ATL cells
Next we examined the effect of AG490 on the growth of
HTLV-1-infected T-cell lines and primary ATL cells. HTLV-
1-infected T-cell lines were treated with different concen-
tration of AG490 (0, 25 or 50 µM) and cell numbers were
counted 24 and 48 h after treatment. AG490 suppressed
the growth of HTLV-1-infected T-cell lines in a dose and
time dependent manner (Figure 4A). The antiproliferative
effects of AG490 against primary ATL cells and PBMCs
from healthy donors were measured by WST-8 method
(Cell Counting Kit-8; Wako Chemical, Osaka, Japan)
based on the MTT assay as described previously [20]. Cell
viability was determined as percentage of the control
(without AG490). AG490 also inhibited the growth of
PBMCs from ATL patients (ATL #1–7 in Figure 4B). In
comparison, the cell growth inhibitory effect on PBMCs
from healthy donors was weak (Normal #1–3 in Figure
4B). These findings indicate that AG490 inhibits the
AG490 inhibits constitutive activation of Jak and Stat in  HTLV-1-infected T-cell lines and primary ATL cells Figure 3
AG490 inhibits constitutive activation of Jak and Stat 
in HTLV-1-infected T-cell lines and primary ATL 
cells. (A and B) HTLV-1-infected T-cell lines were treated 
with increasing concentrations of AG490 for 24 h. (C) Pri-
mary ATL cells were treated with (+) or without (-) 50 µM 
AG490 for 24 h. Phosphorylation status of Stat3 and Stat5 
was assessed by Western blot analysis. (D) HTLV-1-infected 
T-cell lines were treated with increasing concentrations of 
AG490 for 24 h. Phosphorylation status of Jak1, Jak2 and Jak3 
were assessed by Western blot analysis. (E) AG490 does not 
affect phosphorylation of other phosphor-protein that is not 
regulated by Jak-Stat pathway. HTLV-1-infected T-cell lines 
were treated with (+) or without (-) 50 µM AG490 for 24 h. 
Phosphorylation status of GSK-3β was assessed by Western 
blot analysis. (F) AG490 inhibits constitutive Stat3- and Stat5-
DNA binding in HTLV-1-infected T-cell lines. Nuclear 
extracts were isolated from HTLV-1-infected T-cell lines 
treated with (+) or without (-) 50 µM AG490 for 24 h. Stat-
DNA binding activity was assessed by EMSA using SIE or β-
casein probe.Retrovirology 2006, 3:22 http://www.retrovirology.com/content/3/1/22
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growth of cells infected with HTLV-1 but not that of unin-
fected PBMCs.
AG490 induces cell-cycle arrest and apoptosis of HTLV-1-
infected T-cell lines
We then investigated the effect of AG490 on cell-cycle dis-
tribution in HTLV-1-infected T-cell lines (Figure 4C). Cells
were treated with 25 µM AG490 for 24 h. Twenty-five µM
AG490 inhibited cell-cycle progression, as demonstrated
by the increased proportion of cells in G1 phase [MT-2:
from 52% to 72%; HUT-102: from 51% to 83%; ED-
40515(-): from 35% to 44%] and decreased percentage of
cells in S phase [MT-2: from 36% to 18%; HUT-102: from
36% to 8%; ED-40515(-): from 51% to 43%], indicating
G1 cell-cycle arrest. The effect of AG490 on apoptosis was
examined by the Annexin-V method. Annexin-V binding
reveals the phosphatidylserine molecules have been
flipped out from the inner to the outer cell surface during
apoptosis. Cells were treated with 50 µM AG490 for 48 h.
AG490 increased the proportion of cells positive for
Annexin-V in all cell lines (Figure 4D), indicating the
increased apoptosis of AG490-treated cells. Thus, AG490
is both anti-proliferative and pro-apoptotic in HTLV-1-
infected T-cell lines.
Expression of cell-cycle associated genes in AG490-treated 
HTLV-1-infected T-cell lines and ATL cells
We next examined whether AG490 induces G1 cell-cycle
arrest by modulating the expression of G1 cyclins, cyclin
D1 and cyclin D2, which are associated with cell-cycle
progression from G1 to S phase. AG490 decreased cyclin
D2 expression, however, the expression of cyclin D1 was
almost unchanged (Figure 5A). Cell-cycle progression
from G1 to S phase is also regulated by G1 cyclin-depend-
ent kinases; Cdk4 and Cdk6, which bind and activate the
cyclin D. AG490 inhibited the expression of Cdk4 in a
dose-dependent manner but not that of Cdk6 protein
(Figure 5A). These results suggest that AG490 induces G1
arrest by reducing the expression of cyclin D2 and Cdk4,
which regulate the G1-S transition. The p53/p21 pathway
also plays a critical role in regulating the G1-S transition.
We examined the effects of AG490 on p53 and p21 levels
in HTLV-1-infected T-cell lines. Expression of p53 protein
was increased in AG490 treated MT-2 and HUT-102 cells.
In contrast, p53 protein was almost undetectable in ED-
40515(-) cells and remained unchanged in AG490-treated
cells. p21 was induced in MT-2 and HUT-102 cells and
remained undetectable in ED-40515(-) cells. These results
indicate that p21 activation can also contribute to AG490-
induced G1 arrest in p53-competent cells. AG490-treated
ED-40515(-) cells did not induce G1 arrest as much as MT-
2 and HUT-102 cells (Figure 4D). This might be due to
absence of p53 and p21 proteins in AG490-treated ED-
40515(-) cells. Cell-cycle progression from G1 to S phase
is also regulated by Serin/Threonin kinase Pim-1 and c-
AG490 reduces cell growth of HTLV-1-infected T-cell lines  and primary ATL cells Figure 4
AG490 reduces cell growth of HTLV-1-infected T-cell 
lines and primary ATL cells. (A) HTLV-1-infected T-cell 
lines (5 × 104/mL) were treated with 0, 25 or 50 µM AG490 
for 24 or 48 h. Cell numbers were counted in triplicate by 
Trypan blue dye exclusion method. Data are expressed as 
the mean values of viable cell numbers. (B) Primary ATL cells 
from seven patients (ATL #1–7) and PBMCs from three 
healthy donors (Normal #1–3) were treated with 0, 25 or 50 
µM AG490 for 48 h. Cell growth was assessed by the WST-8 
method. Data are expressed as the percentages of control 
(untreated cells). (C) Cell-cycle analysis of HTLV-1-infected 
T-cell lines treated with AG490. Cells were treated in the 
absence (-) or presence (+) of 25 µM AG490 for 24 h. DNA 
content was analyzed by flow cytometry with propidium 
iodide staining. G1, S and G2/M indicate the stages of the cell-
cycle. Data represent mean percentages of cells at each cell-
cycle from three independent experiments. (D) Induction of 
apoptosis in HTLV-1-infected T-cell lines by AG490. Cells 
were treated in the absence (open bar) or presence (solid 
bar) of 50 µM AG490 for 48 h and stained with Annexin-V. 
Apoptosis was analyzed by flow cytometry. Data represent 
mean percentages of apoptotic cells from three independent 
experiments.Retrovirology 2006, 3:22 http://www.retrovirology.com/content/3/1/22
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Myc through Cdc25A activation [21,22]. pim-1 and c-myc
Effects of AG490 on the expression of cell-cycle associated  proteins Figure 5
Effects of AG490 on the expression of cell-cycle asso-
ciated proteins. HTLV-1-infected T-cell lines were treated 
with increasing concentrations of AG490 for 24 h. Amounts 
of cyclin D1, cyclin D2, Cdk4, Cdk6, p53, p21, Pim-1 and c-
Myc were determined by Western blot analysis. (B) Primary 
ATL cells were treated with (+) or without (-) 50 µM AG490 
for 24 h. The expression of cyclin D2 and p53 was assessed 
by Western blot analysis. The amount of actin is shown as a 
loading control.
Effects of AG490 on the expression of anti-apoptotic pro- teins Figure 6
Effects of AG490 on the expression of anti-apoptotic 
proteins. (A) HTLV-1-infected T-cell lines were treated 
with increasing concentrations of AG490 for 24 h. Amounts 
of c-IAP-2, XIAP, survivin, Bcl-2, Bcl-xL and Tax were deter-
mined by Western blot analysis. (B) Primary ATL cells were 
treated with (+) or without (-) 50 µM AG490 for 24 h. The 
expression of c-IAP2, XIAP, survivin and Tax was assessed by 
Western blot analysis. (C) HUT-102 cells were treated with 
(+) or without (-) 50 µM AG490 for 24 h. The expression of 
HTLV-1 viral proteins, envelope glycoprotein gp46 and p19 
core protein was assessed by Western blot analysis. The 
amount of actin is shown as a loading control.Retrovirology 2006, 3:22 http://www.retrovirology.com/content/3/1/22
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genes are both direct targets of Stat [23,24]. AG490
decreased the expression of these proteins in all HTLV-1-
infected T-cell lines (Figure 5A). AG490 also reduced the
expression of cyclin D2 and increased the expression of
p53 in freshly isolated ATL cells (Figure 5B). However,
other proteins that were altered by AG490 in HTLV-1-
infected T-cell lines were undetectable and AG490 did not
change the expression of these genes in primary ATL cells
(data not shown).
Expression of anti-apoptotic genes in AG490-treated 
HTLV-1-infected T-cell lines and ATL cells
We also examined the effects of AG490 on the expression
of IAP and Bcl-2 family members, which determine the
response to apoptotic stimuli. AG490 significantly altered
the expression of XIAP and survivin, which are Stat-regu-
lated genes [25,26], but not that of Bcl-xL protein in all
tested cell lines (Figure 6A). Downregulation of Bcl-2
expression by AG490 was only noted in HUT-102 cells.
The expression of c-IAP2 was downregulated in HUT-102
and ED-40515(-), but not in MT-2 cells. These results
indicated that AG490-induced apoptosis of HTLV-1-
infected T-cells is mediated by downregulation of c-IAP2,
XIAP, survivin and Bcl-2 expression. AG490 reduced the
expression of all these genes in freshly isolated ATL cells
(Figure 6B). Bcl-2 protein was undetectable in primary
ATL cells (data not shown). Cyclin D2 [27,28], Cdk4 [29],
XIAP [30] and survivin [31] are Tax-responsive genes,
therefore, we also examined the level of Tax expression in
these cells. AG490 did not alter Tax protein levels in MT-
2 and HUT-102 cells (Figure 6A). Tax protein remained at
undetectable levels in ED-40515(-) and primary ATL cells
after AG490 treatment (Figures 6A and 6B). Therefore, the
altered expression of cyclin D2, Cdk4, XIAP and survivin
was not attributable to Tax downregulation. We also
examined whether AG490 could change the expression
levels of other viral proteins. The expression levels of
HTLV-1 envelope 46 kDa glycoprotein (gp46) and 19 kDa
core protein (p19) were not changed by AG490 treatment
in HUT-102 cells (Figure 6C), suggesting that the AG490
does not drop the virus levels in these cells and the effects
of AG490 on these cells are not due to downregulation of
viral proteins.
Discussion
In this study, we demonstrated that Stat3 and Stat5 are
constitutively activated in HTLV-1-infected T-cell lines
and primary ATL cells, but not in HTLV-1-negative T-cell
lines. Using AG490, a Jak-specific inhibitor, we showed
that the activation of Stat3 and Stat5 is mediated by the
constitutive phosphorylation of Jak proteins. Further-
more, we showed that AG490 inhibits the growth of
HTLV-1-infected T-cell lines and primary ATL cells by
inducing G1 cell-cycle arrest and apoptosis, but not that of
normal PBMCs. Our results indicate that constitutive acti-
vation of Jak-Stat is responsible for the proliferation and
survival of ATL cells.
The mechanism for the constitutive activation of Jak-Stat
after HTLV-1 infection is still unclear. HTLV-1 transform-
ing protein Tax is considered to play a critical role in
leukemogenesis and development of ATL. However, our
data showed no correlation between Stat activation and
Tax protein expression in HTLV-1-infected T-cell lines.
Previous reports are consistent with our data in their lack
of support for the involvement of Tax or the autocrine
production of IL-2 or IL-15 in Stat-activation of HTLV-1-
infected T-cell lines and primary ATL cells [12,14]. Expres-
sion of Stat5 mRNA is induced by HTLV-1 Tax using JPX-
9 cells [32]. Using this cell line, we showed that Tax
induced neither the expression nor the phosphorylation
of Stat3 and Stat5 proteins. A T-cell line denoted Tax, in
which a herpes samiri-based vector drives Tax gene expres-
sion, does not exhibit constitutive Stat binding activity
[12]. We also showed that ATL-derived T-cell line, ED-
40515(-) and primary ATL cells which did not express Tax
protein at detectable level, expressed Stat proteins in the
phosphorylated form. It should be noted that the leuke-
mic cells in vivo generally do not express Tax by several
mechanisms [33]. Thus, it is unlikely that Tax is involved
in the induction or activation of Stat proteins or repre-
sents a target of anti-ATL drugs. Previously, Nicot and col-
leagues [34] reported that the p12I protein, encoded by
the pX open reading frame I of HTLV-1, binds to the IL-2R
β chain, resulting in activation of Stat5 through Jak1 and
Jak3 activation. However, the mechanisms for the Jak2
activation in HTLV-1-infected T-cells are not elucidated.
Our data demonstrating that inhibition of Stat activity led
to apoptosis in HTLV-1-infected T-cell lines and primary
ATL cells are in line with a previous study reporting induc-
tion of apoptosis by ectopic expression of a dominant-
negative form of Stat5 in MT-2 cells [25]. Our data of a
weaker effect of AG490 on the growth of normal PBMCs
than that of ATL cells were consistent with a previous
report showing that AG490 has no significant effect on the
growth of normal B and T cells in vitro [16]. In contrast to
our data, Kirken and colleagues [18] reported that
although AG490 blocks the phosphorylation of Stat5 and
Jak3, and DNA-binding activity of Stat5 of HTLV-1-trans-
formed T-cell lines, MT-2 and HUT-102, it fails to disrupt
the growth of these leukemic cells. Although we used
lower concentration of AG490 (50 µM Max.) than this
group (100 µM Max.), we observed a dose-dependent
inhibition of cell growth in these cells by AG490. The pre-
cise reason for these differences is not clear, however, we
cannot exclude the possibility that these differences could
be attributable to variations in experimental conditions
such as serum concentration (1% vs. 10%) in tissue cul-
ture medium. Perhaps for AG490 mediated growth inhib-Retrovirology 2006, 3:22 http://www.retrovirology.com/content/3/1/22
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itory effect in HTLV-1-infected T-cell lines and ATL cells,
active protein synthesis is required.
Previous study suggested that AG490 is a Jak2-specific
inhibitor and blocks leukemic cell growth of acute lym-
phoblastic leukemia [16]. Our data showed that AG490
also inhibited phosphorylation of Jak1 and Jak3 of MT-2
and HUT-102. Thus, three constitutively phosphorylated
Jak proteins in HTLV-1-infected T-cell lines were inhibited
by AG490. These results are consistent with recent studies
reporting that AG490 inhibits Jak1 activated by IL-6 in
myeloma cells or IL-2-induced Jak3 activity in an IL-2-
dependent T-cell line [17,35], suggesting that the afore-
mentioned three Jak proteins share AG490 sensitivity.
Interestingly, AG490 does not affect other lymphocyte
tyrosine kinases [16]. This may also account for the fact
that AG490 is well-tolerated in mice [16,36].
Conclusion
We have demonstrated that constitutive activation of Jak-
Stat is responsible for the proliferation and survival of ATL
cells. Previously we showed that NF-κB pathway is consti-
tutively activated in HTLV-1-infected T-cell lines and pri-
mary ATL cells [37] and inhibition of this pathway
suppresses the growth of these cells [38,39]. In addition to
NF-κB pathway, our findings in this study indicate that
inhibition of the Jak-Stat pathway offers a new approach
for ATL treatment. Furthermore, AG490 kinase inhibitor
is well tolerated in vivo, and thus presents a useful agent
for this novel anti-ATL therapeutic approach.
Methods
Cell lines
The HTLV-1-uninfected T-cell leukemia cell lines; Jurkat,
MOLT-4, CCRF-CEM and HTLV-1-infected T-cell lines;
MT-2 [40], HUT-102 [1] and ED-40515(-) [41] [HUT-102
was a generous gift from the Fujisaki Cell Center, Hayash-
ibara Biomedical Laboratories, Okayama, Japan, ED-
40515(-) was from Dr. M. Maeda, Kyoto University,
Kyoto, Japan] were maintained in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine
serum, 50 U/ml penicillin and 50 µg/ml streptomycin
(Sigma-Aldrich, St. Louis, MO) at 37°C in 5% CO2. MT-2
is an HTLV-1-transformed T-cell line, established by an in
vitro coculture protocol. The clonal origin of HUT-102 was
not determined. ED-40515(-) is a leukemia T-cell line
derived from a patient with ATL. JPX-9 (kindly provided
by Dr. M. Nakamura, Tokyo Medical and Dental Univer-
sity, Tokyo, Japan) is a subclone of Jurkat cells expressing
Tax under the control of the metallothionein promoter
[42]. Expression of Tax was induced by addition of CdCl2
to a final concentration of 20 µM.
Reagents
AG490 was purchased from Calbiochem (La Jolla, CA).
The anti-Tax (Lt-4), anti-gp46 (REY-7) and anti-p19 (GIN-
7) antibodies were described previously [43-45]. The anti-
Stat3, anti-phospho-Stat3 (Tyr705), anti-phospho-Stat5
(Tyr694) and anti-phospho-GSK-3β (Ser9) antibodies
were purchased from Cell Signaling Technology (Beverly,
MA). The anti-phospho-Jak1 (Tyr 1022/Tyr 1023), anti-
phospho-Jak2 (Tyr 1007/Tyr 1008), anti-phospho-Jak3
(Try980), anti-cyclin D2, anti-Pim-1, anti-survivin and
anti-c-IAP2 antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The anti-cyclin D1 and
anti-XIAP antibodies were purchased from Medical & Bio-
logical Laboratories (Nagoya, Japan). The anti-Cdk4, anti-
Cdk6, anti-p53, anti-p21, anti-c-Myc, anti-Bcl-2 and anti-
actin antibodies were from NeoMarkers (Fremont, CA).
The anti-Stat5 and anti-Bcl-xL antibodies were from BD
transduction Laboratories (San Jose, CA). Horseradish-
peroxidase-conjugated secondary antibodies were pur-
chased from Amersham Biosciences (Piscataway, NJ).
Western blot analysis
Western blot analysis was performed as described previ-
ously [46]. In brief, whole cell lysates were subjected to
SDS-PAGE and electroblotted onto polyvinylidene difluo-
ride membranes (Millipore, Billerica, MA), and then ana-
lyzed for immunoreactivity with the appropriate primary
and secondary antibodies as indicated in the figures. Reac-
tion products were visualized using Enhanced Chemilu-
minescence reagent, according to the instructions
provided by the manufacturer (Amersham Pharmacia,
Uppsala, Sweden).
EMSA
Nuclear extracts were prepared from AG490-treated and
untreated cells and Stat3- or Stat5-DNA binding activity
was analyzed by EMSA as described previously [47,48].
The probes or competitors used were prepared by anneal-
ing the following sense and antisense synthetic oligonu-
cleotides: Stat3 consensus binding motif (SIE) derived
from c-fos promoter 5'-gatcGACATTTCCCGTAAATCG-3',
SIE mutant 5'-gatcGACATTTCCCGTCCCGCG-3', Stat5
consensus binding motif (β-casein) derived from β-casein
promoter 5'-gatcAGATTTCTAGGAATTCAAATC-3' and β-
casein mutant 5'-gatcAGATTTAGTTTAATTCAAATC-3'. To
identify Stat proteins in the DNA-protein complex
revealed by EMSA, we used specific antibodies for various
Stat family proteins including Stat1, Stat2, Stat3, Stat4 and
Stat5 (Santa Cruz Biotechnology), to elicit a supershift
DNA-protein complex formation.
Patient samples
PBMCs from three healthy volunteers (Normal #1–3) or
patients with the acute (ATL #1–4, 6 and 7) or chronic
(ATL #5) type of ATL were analyzed. The diagnosis of ATLRetrovirology 2006, 3:22 http://www.retrovirology.com/content/3/1/22
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was based on clinical features, hematological characteris-
tics, presence of serum antibodies to ATL-associated anti-
gens and presence of HTLV-1 proviral genome in DNA
from leukemic cells. PBMCs were isolated by Ficoll/
Hypaque (Pharmacia LKB, Piscataway, NJ) using density
gradient centrifugation. Each patient had more than 90%
leukemic cells in the blood at the time of analysis. The
study protocol was approved by the Human Ethics Review
Committee of University of the Ryukyus, and a signed
consent form was obtained from each subject.
Assays for cellular proliferation
The antiproliferative effects of AG490 against HTLV-1-
infected T-cell lines were measured by the Trypan blue dye
exclusion method. The 5 × 104 cells were incubated in the
presence of 0, 25 or 50 µM AG490 in a final volume of 1
mL at 37°C. The cell numbers were counted by the Trypan
blue dye exclusion method after 24 and 48 h treatment.
The antiproliferative effects of AG490 against primary ATL
cells and PBMCs from healthy donors were measured by
WST-8 method (Cell Counting Kit-8; Wako Chemical,
Osaka, Japan) based on the MTT assay as described previ-
ously [20]. Briefly, the 1 × 105 cells were incubated in trip-
licate in 96-well microculture plates in the presence of 0,
25 or 50 µM AG490 in a final volume of 0.1 ml for 48 h
at 37°C. Thereafter, 5 µl Cell Counting Kit-8 solution [5
mM WST-8, 0.2 mM 1-Methoxy PMS (5-methylphenazin-
ium methylsulfate) and 150 mM NaCl] was added, and
the cells were further incubated for another 4 h. The
number of surviving cells was measured by a 96-well mul-
tiscanner autoreader at optical density of 450 nm. Cell
viability was determined as percentage of the control
(without AG490).
Cell-cycle analysis
Cells were plated at a density of 1 × 105/ml in 60-mm tis-
sue culture dish. Twelve hours after plating, cells were
exposed to 25 µM AG490 for 24 h. Cell-cycle analysis was
performed with the CycleTEST PLUS DNA reagent kit
(Becton Dickinson, San Jose, CA). Briefly, cells were
washed with a buffer solution containing sodium citrate,
sucrose and dimethyl sulfoxide, suspended in a solution
containing RNase A, and stained with 125 µg/ml propid-
ium iodide for 10 min. Cell suspensions were analyzed on
a FACS Calibur (Becton Dickinson) using CellQuest. The
cell population at each cell-cycle phase was determined
with ModiFit software.
Assays for apoptosis
Cells were plated at a density of 1 × 105/ml in 60-mm tis-
sue culture dish. Twelve hours after plating, cells were
exposed to 50 µM AG490 for 48 h. Apoptosis was quanti-
fied by staining with Annexin-V-Fluos (Roche Diagnos-
tics, Mannheim, Germany) according to the instructions
supplied by the manufacturer. Cells were analyzed on a
FACS Calibur using CellQuest.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MT contributed to the concept and design, interpreted
and analyzed the data, provided drafting of the article,
provided critical revisions and important intellectual con-
tent, collected and assembled the data. HK, JU, TO and
TM collected and assembled the data. MM, YT and KO
provided study materials and critical revisions and impor-
tant intellectual content. NM contributed to the concept
and design, provided critical revisions and important
intellectual content, obtained a funding source, provided
administrative support. All authors read and approved the
final manuscript.
Acknowledgements
This work was supported in part by a grant-in-aid from the Japan Society 
for the Promotion of Science, by a grant-in-aid from the Ministry of Educa-
tion, Culture, Sports, Science and Technology of Japan.
References
1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC:
Detection and isolation of type C retrovirus particles from
fresh and cultured lymphocytes of a patient with cutaneous
T-cell lymphoma.  Proc Natl Acad Sci U S A 1980,
77(12):7415-7419.
2. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita
KI, Shirakawa S, Miyoshi I: Adult T-cell leukemia: antigen in an
ATL cell line and detection of antibodies to the antigen in
human sera.  Proc Natl Acad Sci U S A 1981, 78(10):6476-6480.
3. Yoshida M, Miyoshi I, Hinuma Y: Isolation and characterization
of retrovirus from cell lines of human adult T-cell leukemia
and its implication in the disease.  Proc Natl Acad Sci U S A 1982,
79(6):2031-2035.
4. Tajima K: The 4th nation-wide study of adult T-cell leukemia/
lymphoma (ATL) in Japan: estimates of risk of ATL and its
geographical and clinical features. The T- and B-cell Malig-
nancy Study Group.  Int J Cancer 1990, 45(2):237-243.
5. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M,
Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M,
Tobinai K, Hotta T, Shimoyama M: A new G-CSF-supported com-
bination chemotherapy, LSG15, for adult T-cell leukaemia-
lymphoma: Japan Clinical Oncology Group Study 9303.  Br J
Haematol 2001, 113(2):375-382.
6. Franchini G: Molecular mechanisms of human T-cell leukemia/
lymphotropic virus type I infection.  Blood 1995,
86(10):3619-3639.
7. Schindler C, Darnell JEJ: Transcriptional responses to polypep-
tide ligands: the JAK-STAT pathway.  Annu Rev Biochem 1995,
64:621-651.
8. Darnell JEJ: STATs and gene regulation.  Science 1997,
277(5332):1630-1635.
9. Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis.
Oncogene 2000, 19(21):2474-2488.
10. Coffer PJ, Koenderman L, de Groot RP: The role of STATs in
myeloid differentiation and leukemia.  Oncogene 2000,
19(21):2511-2522.
11. Lin TS, Mahajan S, Frank DA: STAT signaling in the pathogenesis
and treatment of leukemias.  Oncogene 2000, 19(21):2496-2504.
12. Migone TS, Lin JX, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G,
Leonard WJ: Constitutively activated Jak-STAT pathway in T
cells transformed with HTLV-I.  Science 1995, 269(5220):79-81.Retrovirology 2006, 3:22 http://www.retrovirology.com/content/3/1/22
Page 10 of 10
(page number not for citation purposes)
13. Mulloy JC, Migone TS, Ross TM, Ton N, Green PL, Leonard WJ, Fran-
chini G: Human and simian T-cell leukemia viruses type 2
(HTLV-2 and STLV-2pan-p) transform T cells independently
of Jak/STAT activation.  J Virol 1998, 72(5):4408-4412.
14. Takemoto S, Mulloy JC, Cereseto A, Migone TS, Patel BK, Matsuoka
M, Yamaguchi K, Takatsuki K, Kamihira S, White JD, Leonard WJ,
Waldmann T, Franchini G: Proliferation of adult T cell leukemia/
lymphoma cells is associated with the constitutive activation
of JAK/STAT proteins.  Proc Natl Acad Sci U S A 1997,
94(25):13897-13902.
15. Levitzki A: Tyrosine kinases as targets for cancer therapy.  Eur
J Cancer 2002, 38 Suppl 5:S11-8.
16. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z,
Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM:
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhib-
itor.  Nature 1996, 379(6566):645-648.
17. Wang LH, Kirken RA, Erwin RA, Yu CR, Farrar WL: JAK3, STAT,
and MAPK signaling pathways as novel molecular targets for
the tyrphostin AG-490 regulation of IL-2-mediated T cell
response.  J Immunol 1999, 162(7):3897-3904.
18. Kirken RA, Erwin RA, Wang L, Wang Y, Rui H, Farrar WL: Func-
tional uncoupling of the Janus kinase 3-Stat5 pathway in
malignant growth of human T cell leukemia virus type 1-
transformed human T cells.  J Immunol 2000, 165(9):5097-5104.
19. Koiwa T, Hamano-Usami A, Ishida T, Okayama A, Yamaguchi K,
Kamihira S, Watanabe T: 5'-long terminal repeat-selective CpG
methylation of latent human T-cell leukemia virus type 1
provirus in vitro and in vivo.  J Virol 2002, 76(18):9389-9397.
20. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K: A
combined assay of cell viability and in vitro cytotoxicity with
a highly water-soluble tetrazolium salt, neutral red and crys-
tal violet.  Biol Pharm Bull 1996, 19(11):1518-1520.
21. Rainio EM, Sandholm J, Koskinen PJ: Cutting edge: Transcrip-
tional activity of NFATc1 is enhanced by the Pim-1 kinase.  J
Immunol 2002, 168(4):1524-1527.
22. Galaktionov K, Chen X, Beach D: Cdc25 cell-cycle phosphatase
as a target of c-myc.  Nature 1996, 382(6591):511-517.
23. Borg KE, Zhang M, Hegge D, Stephen RL, Buckley DJ, Magnuson NS,
Buckley AR: Prolactin regulation of pim-1 expression: positive
and negative promoter elements.  Endocrinology 1999,
140(12):5659-5668.
24. Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K,
Hibi M, Hirano T: STAT3 is required for the gp130-mediated
full activation of the c-myc gene.  J Exp Med 1999, 189(1):63-73.
25. Mohapatra S, Chu B, Wei S, Djeu J, Epling-Burnette PK, Loughran T,
Jove R, Pledger WJ: Roscovitine inhibits STAT5 activity and
induces apoptosis in the human leukemia virus type 1-trans-
formed cell line MT-2.  Cancer Res 2003, 63(23):8523-8530.
26. Aoki Y, Feldman GM, Tosato G: Inhibition of STAT3 signaling
induces apoptosis and decreases survivin expression in pri-
mary effusion lymphoma.  Blood 2003, 101(4):1535-1542.
27. Huang Y, Ohtani K, Iwanaga R, Matsumura Y, Nakamura M: Direct
trans-activation of the human cyclin D2 gene by the onco-
gene product Tax of human T-cell leukemia virus type I.
Oncogene 2001, 20(9):1094-1102.
28. Mori N, Fujii M, Hinz M, Nakayama K, Yamada Y, Ikeda S, Yamasaki
Y, Kashanchi F, Tanaka Y, Tomonaga M, Yamamoto N: Activation
of cyclin D1 and D2 promoters by human T-cell leukemia
virus type I tax protein is associated with IL-2-independent
growth of T cells.  Int J Cancer 2002, 99(3):378-385.
29. Iwanaga R, Ohtani K, Hayashi T, Nakamura M: Molecular mecha-
nism of cell cycle progression induced by the oncogene prod-
uct Tax of human T-cell leukemia virus type I.  Oncogene 2001,
20(17):2055-2067.
30. Kawakami A, Nakashima T, Sakai H, Urayama S, Yamasaki S, Hida A,
Tsuboi M, Nakamura H, Ida H, Migita K, Kawabe Y, Eguchi K: Inhibi-
tion of caspase cascade by HTLV-I tax through induction of
NF-κB nuclear translocation.  Blood 1999, 94(11):3847-3854.
31. Kawakami H, Tomita M, Matsuda T, Ohta T, Tanaka Y, Fujii M, Hatano
M, Tokuhisa T, Mori N: Transcriptional activation of survivin
through the NF-κB pathway by human T-cell leukemia virus
type I tax.  Int J Cancer 2005, 115:967-974.
32. Nakamura N, Fujii M, Tsukahara T, Arai M, Ohashi T, Wakao H, Kan-
nagi M, Yamamoto N: Human T-cell leukemia virus type 1 Tax
protein induces the expression of STAT1 and STAT5 genes
in T-cells.  Oncogene 1999, 18(17):2667-2675.
33. Matsuoka M: Human T-cell leukemia virus type I (HTLV-I)
infection and the onset of adult T-cell leukemia (ATL).  Retro-
virology 2005, 2(1):27.
34. Nicot C, Mulloy JC, Ferrari MG, Johnson JM, Fu K, Fukumoto R, Tro-
vato R, Fullen J, Leonard WJ, Franchini G: HTLV-1 p12I protein
enhances STAT5 activation and decreases the interleukin-2
requirement for proliferation of primary human peripheral
blood mononuclear cells.  Blood 2001, 98(3):823-829.
35. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B: JAK2 tyrosine
kinase inhibitor tyrphostin AG490 downregulates the
mitogen-activated protein kinase (MAPK) and signal trans-
ducer and activator of transcription (STAT) pathways and
induces apoptosis in myeloma cells.  Br J Haematol 2000,
109(4):823-828.
36. Constantin G, Laudanna C, Brocke S, Butcher EC: Inhibition of
experimental autoimmune encephalomyelitis by a tyrosine
kinase inhibitor.  J Immunol 1999, 162(2):1144-1149.
37. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW,
Yamamoto N: Constitutive activation of NF-kB in primary
adult T-cell leukemia cells.  Blood 1999, 93(7):2360-2368.
38. Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y,
Tomonaga M, Yamamoto N, Fujii M: Bay 11-7082 inhibits tran-
scription factor NF-kB and induces apoptosis of HTLV-I-
infected T-cell lines and primary adult T-cell leukemia cells.
Blood 2002, 100(5):1828-1834.
39. Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Takasu
N, Matsuda T, Ohta T, Tanaka Y, Ohshiro K, Mori N: Curcumin
(diferuloylmethane) inhibits constitutive active NF-kB, lead-
ing to suppression of cell growth of human T-cell leukemia
virus type I-infected T-cell lines and primary adult T-cell
leukemia cells.  Int J Cancer 2006, 118(3):765-772.
40. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y,
Nagata K, Hinuma Y: Type C virus particles in a cord T-cell line
derived by co-cultivating normal human cord leukocytes and
human leukaemic T cells.  Nature 1981, 294(5843):770-771.
41. Maeda M, Shimizu A, Ikuta K, Okamoto H, Kashihara M, Uchiyama T,
Honjo T, Yodoi J: Origin of human T-lymphotrophic virus I-
positive T cell lines in adult T cell leukemia. Analysis of T cell
receptor gene rearrangement.  J Exp Med 1985,
162(6):2169-2174.
42. Nagata K, Ohtani K, Nakamura M, Sugamura K: Activation of
endogenous c-fos proto-oncogene expression by human T-
cell leukemia virus type I-encoded p40tax protein in the
human T-cell line, Jurkat.  J Virol 1989, 63(8):3220-3226.
43. Tanaka Y, Yoshida A, Takayama Y, Tsujimoto H, Tsujimoto A, Hayami
M, Tozawa H: Heterogeneity of antigen molecules recognized
by anti-tax1 monoclonal antibody Lt-4 in cell lines bearing
human T cell leukemia virus type I and related retroviruses.
Jpn J Cancer Res 1990, 81(3):225-231.
44. Tanaka Y, Yasumoto M, Nyunoya H, Ogura T, Kikuchi M, Shimotohno
K, Shiraki H, Kuroda N, Shida H, Tozawa H: Generation and char-
acterization of monoclonal antibodies against multiple
epitopes on the C-terminal half of envelope gp46 of human
T-cell leukemia virus type-I (HTLV-I).  Int J Cancer 1990,
46(4):675-681.
45. Tanaka Y, Lee B, Inoi T, Tozawa H, Yamamoto N, Hinuma Y: Anti-
gens related to three core proteins of HTLV-I (p24, p19 and
p15) and their intracellular localizations, as defined by mon-
oclonal antibodies.  Int J Cancer 1986, 37(1):35-42.
46. Tomita M, Choe J, Tsukazaki T, Mori N: The Kaposi's sarcoma-
associated herpesvirus K-bZIP protein represses transform-
ing growth factor b signaling through interaction with CREB-
binding protein.  Oncogene 2004, 23(50):8272-8281.
47. Mori N, Fujii M, Iwai K, Ikeda S, Yamasaki Y, Hata T, Yamada Y, Tan-
aka Y, Tomonaga M, Yamamoto N: Constitutive activation of
transcription factor AP-1 in primary adult T-cell leukemia
cells.  Blood 2000, 95(12):3915-3921.
48. Mori N, Prager D: Transactivation of the interleukin-1α pro-
moter by human T-cell leukemia virus type I and type II Tax
proteins.  Blood 1996, 87(8):3410-3417.